Last updated: March 16, 2021
Sponsor: Singapore General Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Obesity
Diabetes Prevention
Metabolic Disorders
Treatment
N/AClinical Study ID
NCT04658134
SGH-ENDO-Glycine002
Ages 21-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age: 21-65 years
- BMI ≥ 32.5 kg/m2
- Able to provide informed consent
- Able to maintain present diet throughout the study duration
Exclusion
Exclusion Criteria:
- Weight > 150 kg
- Type 2 Diabetes Mellitus
- Allergy to soy
- Ongoing treatment with weight-loss medications (e.g. orlistat, phentermine,liraglutide)
- Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)
- Renal impairment (estimated creatinine clearance estimated by Cockcroft-Gault Equation < 60 ml/min)
- Haemoglobin concentration < 10 g/L
- Serum alanine aminotransferase or aspartate aminotransferase above 2x upper limit ofnormal
- Uncontrolled hypertension (BP > 180/110 mmHg)
- Pregnancy
- Nursing mothers
- Uncontrolled thyroid disease
- Surgery requiring general anaesthesia within 4-weeks before enrolment
- Psychiatric disorders requiring medication
- Significant alcohol intake (> 1 unit per day for women and > 2 units per day for men)
- Cancer within the last 3-years (except squamous cell and basal cell cancer of theskin)
- Any factors likely to limit adherence to study protocol
Study Design
Total Participants: 20
Study Start date:
January 20, 2021
Estimated Completion Date:
December 15, 2021
Connect with a study center
Singapore General Hospital
Singapore, 169856
SingaporeActive - Recruiting


Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.